All News
Filter News
Found 568 articles
-
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
11/6/2023
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today reported financial results for the quarter ending September 30, 2023, and updates from the Company’s key pipeline developments, business operations and upcoming milestones.
-
Amgen Reports Third Quarter 2023 Financial Results
10/31/2023
Amgen announced financial results for the third quarter of 2023.
-
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
10/19/2023
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT).
-
Kyowa Kirin Announces Three Abstracts and A Symposium at the European Academy of Dermatology and Venereology Congress 2023
10/11/2023
Kyowa Kirin Co., Ltd. announced that post-hoc analysis data from the Phase 2b study of rocatinlimab, an investigational product in patients with moderate-to-severe atopic dermatitis, will be presented at the upcoming European Academy of Dermatology and Venereology Congress 2023 in Berlin, Germany in October 11-14, 2023.
-
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
10/2/2023
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I).
-
Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference
9/26/2023
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to participate in a fireside chat at the Chardan 7th Annual Genetic Medicines Conference in New York City on Tuesday, October 3, at 1:00 p.m. ET.
-
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock - September 13, 2023
9/13/2023
Rocket Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a public offering price of $16.00 per share and to certain investors, pre-funded warrants to purchase 3,126,955 shares of common stock at a price of $15.99 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant.
-
Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors
9/12/2023
Sensorium Therapeutics today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors.
-
Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease
9/12/2023
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that alignment has been reached with the Food and Drug Administration (FDA) on the global Phase 2 pivotal trial of RP-A501 for Danon Disease.
-
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock - September 12, 2023
9/12/2023
Rocket Pharmaceuticals, Inc. announced that it intends to offer and sell shares of its common stock, and to certain investors, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering.
-
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
9/6/2023
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that Company management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference and Cantor Fitzgerald Global Healthcare Conference 2023.
-
ORYZON to Give Updates on Corporate Progress in September
9/5/2023
Oryzon Genomics, S.A. announced today that its management will give an update on corporate progress at several international events in September.
-
Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
8/10/2023
Rocket Pharmaceuticals, Inc. today reported financial results for the quarter ending June 30, 2023, and updates from the Company’s key pipeline developments, business operations and upcoming milestones.
-
Amgen Reports Second Quarter 2023 Financial Results
8/3/2023
Amgen announced financial results for the second quarter of 2023.
-
REGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights
8/2/2023
REGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the second quarter ended June 30, 2023, and recent operational highlights.
-
Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer
7/19/2023
Akari Therapeutics, Plc today announced the appointment of experienced life sciences executive Wendy DiCicco as interim Chief Financial Officer (CFO).
-
Eli Lilly announced Thursday it will acquire former collaborative partner Sigilon Therapeutics to deepen its diabetic foothold with a potentially functional cure for Type 1.
-
Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
6/8/2023
Rocket Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to RP-A601, the Company’s gene therapy candidate for the treatment of plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM).
-
Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease
5/31/2023
Rocket Pharmaceuticals, Inc. today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to RP-A501, the Company’s investigational adeno-associated virus (AAV)-based gene therapy for the treatment of Danon Disease.
-
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD)
5/23/2023
Rocket Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-L301, the Company’s investigational lentiviral-based gene therapy for Pyruvate Kinase Deficiency (PKD).